Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,454
  • Shares Outstanding, K 49,316
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -56,670 K
  • 60-Month Beta 1.95
  • Price/Sales 40.05
  • Price/Cash Flow N/A
  • Price/Book 1.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.48
  • Number of Estimates 3
  • High Estimate -0.45
  • Low Estimate -0.49
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.07 +4.83%
on 10/02/19
3.51 -38.18%
on 09/19/19
-1.03 (-32.19%)
since 09/18/19
3-Month
1.46 +48.63%
on 08/30/19
3.94 -44.92%
on 07/25/19
-1.67 (-43.49%)
since 07/18/19
52-Week
1.46 +48.63%
on 08/30/19
10.37 -79.07%
on 11/08/18
-7.54 (-77.65%)
since 10/18/18

Most Recent Stories

More News
Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock?

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

ABEO : 2.17 (-3.98%)
Abeona Therapeutics (ABEO) Reports Q2 Loss, Misses Revenue Estimates

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ABEO : 2.17 (-3.98%)
Abeona Therapeutics: 2Q Earnings Snapshot

DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Friday reported a loss of $23.9 million in its second quarter.

ABEO : 2.17 (-3.98%)
Abeona Therapeutics: 1Q Earnings Snapshot

DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Friday reported a loss of $18.6 million in its first quarter.

ABEO : 2.17 (-3.98%)
Earnings Preview: Abeona Therapeutics (ABEO) Q1 Earnings Expected to Decline

Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABEO : 2.17 (-3.98%)
Report: Developing Opportunities within Noble, Harris, Jazz Pharmaceuticals, Teradata, Abeona Therapeutics, and Otonomy -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE),...

NE : 1.30 (unch)
HRS : 189.13 (-0.17%)
JAZZ : 119.65 (-1.22%)
TDC : 28.57 (-1.79%)
ABEO : 2.17 (-3.98%)
OTIC : 2.21 (-0.90%)
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Ongoing Phase 1/2 study of ABO-101 enrolling eligible patients with MPS IIIB

ABEO : 2.17 (-3.98%)
Abeona Therapeutics: 4Q Earnings Snapshot

DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Monday reported a loss of $17.5 million in its fourth quarter.

ABEO : 2.17 (-3.98%)
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

On track to initiate Phase 3 VITAL(TM) trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house

ABEO : 2.17 (-3.98%)
Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference

Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced that João Siffert, M.D., Chief...

ABEO : 2.17 (-3.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade ABEO with:

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

2nd Resistance Point 2.50
1st Resistance Point 2.34
Last Price 2.17
1st Support Level 2.06
2nd Support Level 1.94

See More

52-Week High 10.37
Fibonacci 61.8% 6.97
Fibonacci 50% 5.91
Fibonacci 38.2% 4.86
Last Price 2.17
52-Week Low 1.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar